Statistics Collaborative - Design and analysis for biomedical research

PublicationsPublications

Janet Wittes

1 | 2 | 3 | 4 | 5 | 6 | 7 | 8

  • Peduzzi P, Wittes J, Detre K, Holford T. Analysis as-randomized and the problem of non-adherence: an example from the Veterans Affairs Randomized Trial of Coronary Artery Bypass Surgery. Stat Med 1993; 12:1185-1195.
  • Herson J, Wittes J. The use of interim analysis for sample size adjustment. Drug Inf J 1993; 27:753-760.
  • Davis B, Wittes J, Pressel S, Berge K, Hawkins C, Lakatos E, Moye L, Probstfield J. Statistical considerations in monitoring the Systolic Hypertension in the Elderly Program (SHEP). Control Clin Trials 1993; 14:350-361.
  • Piantadosi S, Wittes J. Letter: Politically correct clinical trials. Control Clin Trials 1993; 14:562-567.
  • Wittes J. Subgroup representation in randomized clinical trials. Clinical Trials and Statistics: Proceedings of a Symposium. Board on Mathematical Sciences, National Research Council, National Academy Press, 15-22, 1993.
  • Zucker D, Wittes J. Testing the effect of treatment in experiments with correlated binary outcomes. Biometrics 1992; 48:695-709.
  • Teo K, Yusuf S, Wittes J, Theodoropoulos S, Dhalla N, Aikenhead J, Yacoub M. Preserved left ventricular function during supine exercise in patients after orthotopic cardiac transplantation. Eur Heart J 1992; 13:321-329.
  • Hilner J, McDonald A, Van Horn L, Bragg C, Caan B, Slattery M, Birch R, Smoak C, Wittes J. Quality control of dietary data collection in the CARDIA study. Control Clin Trials 1992; 13:156-169.
  • Follmann D, Wittes J, Cutler J. The use of subjective rankings in clinical trials with an application to cardiovascular disease. Stat Med 1992; 22:427-437.
  • Follmann D, Wittes J, Cutler J. Rejoinder. Stat Med 1992; 11:453-454.
  • Chalmers T, Fisher L, Terrin M, Wittes J. Clinical trials: a reader’s guide. Patient Care 1992; 26:85-102.
    -Response to letter to the editor, 1993; 27:20.
  • Wittes J. Discussion of Chuang-Stein paper “Safety analysis: too much? not enough? and how?” Biopharm Rep 1992; 1:10-11.
  • Yusuf S, Wittes J, Probstfield J, Tyroler H. Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials. JAMA 1991; 266:93-98.
  • The Systolic Hypertension in the Elderly Program (SHEP) cooperative research group Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991; 265:3255-3264.
  • Schucker B, Wittes J, Santanello N, Weber S, McGoldrick D, Donato K, Levy A, Rifkind B. Change in cholesterol awareness and action. Results from national physician and public surveys. Arch Intern Med 1991; 151:666-673.
  • Peduzzi P, Detre K, Wittes J, Holford T. Intent-to-treat analysis and the problem of crossovers. An example from the Veterans Administration coronary bypass surgery study. J Thorac Cardio Sur 1991; 101:481-487.
  • Brantly M, Wittes J, Vogelmeier C, Hubbard R, Fells G, Crystal R. Use of a highly purified alpha 1-antitrypsin standard to establish ranges for the common normal and deficient alpha 1-antitrypsin phenotypes. Chest 1991; 100:703-708.
  • Wittes J, Yusuf S, Probstfield J. Letter: Subgroup analysis of clinical trials. Am J Cardiol 1991; 67:330-331.
  • Yusuf S, Wittes J, Probstfield J. Editorial: Evaluating effects of treatment in subgroups of patients within a clinical trial: the case of non-Q-wave myocardial infarction and beta blockers. Am J Cardiol 1990; 66:220-222.
    -Response to letter to the editor, 1991; 67:330-332.

1 | 2 | 3 | 4 | 5 | 6 | 7 | 8